Clinical Trial Update: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a sequential regimen of GAX-CI chemotherapy followed by Olaparib and pembrolizumab in metastatic pancreatic ductal adenocarcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• GAX-CI
• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: RECRUITING